Comparison of topical treatment methods used in recurrent anterior epistaxis: a randomized clinical trial

Koçak, Hasan Emre; Bilece, Zeki Tolga; Keskin, Mehmet; Ulusoy, Hüseyin Avni; Koç, Arzu Karaman; Kaya, Kamïl Hakan

doi:10.1016/j.bjorl.2019.07.002

Cited by 5 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the clinical interventions, the use of nasal sprays containing decongestants, such as oxymetazoline, was the most common. This preference for decongestant nasal sprays could be attributed to their efficacy in reducing nasal congestion and controlling minor bleeding [28,29]. In contrast, nasal packing with decongestants and hemostatic agents was less frequently used.…”

Section: Discussionmentioning

confidence: 99%

Clinical Presentation and Treatment Patterns of Pediatric Epistaxis: A Single-Center Study

Alruwaili,

Alazmi,

Alenzi

et al. 2024

Cureus

View full text Add to dashboard Cite

Background: Epistaxis, commonly known as nose bleeding, is a prevalent condition in pediatric patients, often managed either at home or in clinical settings. This study aimed to explore the differences in the management of pediatric epistaxis between home and clinical settings, focusing on gender distribution, clinical presentations, and treatment methods.Methods: A retrospective review was conducted, analyzing pediatric epistaxis cases managed both at home and in clinical settings. Data on gender distribution, clinical presentation, and treatment methods were collected and analyzed. Home remedies, first aid management, and clinical interventions like the use of nasal sprays and septoplasty were evaluated.Results: The study found significant differences in gender distribution between home (46.2% males) and clinical settings (61% males). Recurrent nasal bleeding was more common in home settings (75%), whereas more complex cases were predominant in clinical settings. Nasal sprays containing decongestants were widely used in clinical settings (62.1%), contrasting with a preference for first aid measures at home. Surgical interventions like septoplasty were occasionally employed in clinical scenarios. Conclusion:The study highlights distinct approaches to managing pediatric epistaxis in home versus clinical settings. It underscores the importance of tailored treatment strategies, considering the severity and frequency of epistaxis episodes. These findings suggest a need for comprehensive guidelines to assist caregivers and healthcare professionals in effective decision-making for pediatric epistaxis management. The study also emphasizes the necessity for ongoing research and education in this area.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Presentation and Treatment Patterns of Pediatric Epistaxis: A Single-Center Study

Alruwaili,

Alazmi,

Alenzi

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…Anterior nosebleed usually comes from the Little's area or Kiesselbach plexus, which is situated in the anterior part of the septum (5 mm behind the caudal end and 5 mm above the nasal floor) (10). While posterior bleeding comes from the sphenopalatine arteries at the posterior part of the nasal cavity (11).…”

Section: Vascular Anatomy Of the Nosementioning

confidence: 99%

Importance of S-point in the Management of Severe Epistaxis

Al-Ani¹

2023

Al-Kindy Col. Med. J

View full text Add to dashboard Cite

Although severe epistaxis is uncommon, it is serious. The systematic endoscopic nasal examination is an essential step in identifying the bleeding point and aiding electrocauterization. Currently, the S-point, which is located in the superior part of the nasal septum behind the septal body and corresponding to the axilla of the middle concha, is identified in about 30% of cases with severe epistaxis. Cauterization of this point has an excellent rate of controlling the bleeding and preventing its recurrence. We aimed to highlight the significance of the S-point in the management of severe cases of epistaxis.

show abstract

“…A RCT (n=137) examined the effectiveness of five interventions to prevent further epistaxis in patients with recurrent epistaxis (at least 4 episodes in last month). 3 Patients over 18 years old were included in this study if telangiectasias were observed in Little's area on anterior rhinoscopic evaluation and if they were free of comorbid conditions. Patients were randomized to topical antiseptic ointment (n=26, oxytetracylcine hydrochloride–polymyxin B sulphate BID for 2 weeks), topical decongestant ointment (n=25, ephedrine–naphazoline BID for 2 weeks), chemical cauterization (n=26, silver nitrate sticks after local anesthesia with cotton tamponade and 10% lidocaine for 10 minutes), topical antiseptic ointment plus chemical cauterization (n=30), and topical decongestant ointment plus chemical cauterization (n=30).…”

mentioning

confidence: 99%

What is the best treatment of epistaxis in adults?

Magnusson¹,

Raja²,

Stafki³

et al. 2022

EBPR

View full text Add to dashboard Cite

PVSAs (n524,292) had a mean of 80 days from vasectomy to first PVSA, and patients with 3+ total PVSAs (n57,826) had a mean of 70 days from vasectomy to first PVSA.A 2015 retrospective analysis of military service members who had a vasectomy from 2008 to 2013 with one or more PVSAs retrospectively applied the 2012 AUA guidelines compared with their previous institutional protocol requiring repeat PVSAs (N51,623). 2 Of the identified patients, 55% completed a PVSA (N5895). Using the 2012 AUA guidelines definition of successful vasectomy, if the first PVSA was performed ,60 days from the vasectomy, the success rate 87%, compared with if the first PVSA was 61 to 90 days, success rates were 95%, at 91 to 120 days, success was 98%, and at .120 days, success was 100% (ANOVA P,.001). Validity was limited by size and the military population not representing the rest of the population regarding health and age.The 2012 evidence-based AUA vasectomy guidelines define vasectomy success according to a single uncentrifuged sample with azoospermia or rare nonmotile sperm (,100,000 nonmotile sperm/mL). 3 The guideline also stated that timing of first PVSA after vasectomy can occur anytime between 8 and 16 weeks after vasectomy (based on panel consensus).

show abstract

Comparison of topical treatment methods used in recurrent anterior epistaxis: a randomized clinical trial

Cited by 5 publications

References 20 publications

Clinical Presentation and Treatment Patterns of Pediatric Epistaxis: A Single-Center Study

Clinical Presentation and Treatment Patterns of Pediatric Epistaxis: A Single-Center Study

Importance of S-point in the Management of Severe Epistaxis

What is the best treatment of epistaxis in adults?

Contact Info

Product

Resources

About